Intranasal nafarelin compared to subcutaneous triptorelin for triggering final oocyte maturation in ovarian stimulation: a non-inferiority randomised controlled clinical trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516621-31-00

Acronym

FSD-NAF-2024-11

Enrollment

134

Registered

2024-12-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

The number of MII oocytes retrieved.

Detailed description

Total number of oocytes collected, Ovarian Hyperstimulation Syndrome, Other side effects/adverse effects, Cost, Serum LH and FSH levels 12 hours after trigger, Serum LH, FSH and progesterone levels at the time of oocyte collection, Participant reported pain, ease of use and medication preference

Interventions

DRUGDecapeptyl diario 0

DRUG1 mg polvo y disolvente para solución inyectable

DRUGSynarel 200 microgramos solución para pulverización nasal

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The number of MII oocytes retrieved.	—

Secondary

Measure	Time frame
Total number of oocytes collected, Ovarian Hyperstimulation Syndrome, Other side effects/adverse effects, Cost, Serum LH and FSH levels 12 hours after trigger, Serum LH, FSH and progesterone levels at the time of oocyte collection, Participant reported pain, ease of use and medication preference	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026